Xin Lang Cai Jing·2026-01-22 13:25Core Viewpoint - *ST Bio's major asset restructuring plan has failed, leading to the termination of the agreement to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. [1][6] Group 1: Restructuring Details - On January 22, 2026, *ST Bio signed a termination agreement for the acquisition of Hunan Huize Biomedical Technology Co., Ltd. [1][6] - The restructuring plan was initially announced on August 12, 2025, but did not progress to formal implementation due to a lack of substantial agreements among the parties involved [1][6][10] - The failure of the restructuring was attributed to unsuccessful negotiations and a lack of consensus among the transaction parties [10] Group 2: Company Background and Operations - *ST Bio primarily operates in the "biomedical" and "energy-saving and environmental protection" sectors, focusing on the production and sales of related products [3][8] - The company aims to enhance its profitability and risk resistance through the acquisition of Huize Biomedical, which specializes in drug research and clinical evaluation services [3][8] - Huize Biomedical has established long-term partnerships with over 300 pharmaceutical companies and research institutions, completing more than 1,000 technical service projects [3][8] Group 3: Financial Performance - *ST Bio has forecasted a net profit attributable to shareholders of 28.5 million to 32.5 million yuan for 2025, a significant recovery from a loss of 19.846 million yuan in the previous year [4][10] - The company has expanded its operations by acquiring and controlling Loudi Jinhong New Materials Co., Ltd., which has significantly boosted its revenue from recycling businesses [5][10] - The company has also diversified its product offerings, including sales of beauty and health products related to its biomedical business, contributing to revenue and profit growth [5][10]